Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of LNZ101 in Presbyopic Subjects
NCT05753189Phase 3Completed
- Sponsor
- LENZ Therapeutics
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aceclidine, brimonidine tartrate + sodium hyaluronate in presbyopia, sponsored by LENZ Therapeutics. Started Feb 2023; status: completed.
02
Drugs
aceclidinebrimonidine tartrate + sodium hyaluronate
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT05753189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753189.